Cannabinoids Modulate Sleep. They Do Not Fix It.
Chris Emerson, PhD Founder, Chief Scientist, and CEO, LEVEL
Chris Emerson holds a doctorate in small-molecule chemistry from Oregon State University. He is the founder, chief scientist, and CEO of Metta Medical dba LEVEL. His publications appear in Organic Letters, Chemistry: A European Journal and Chemical Communications. He holds US Patents 12,076,442 B1 and 11,596,606 B2 for activated cannabinoid controlled-release formulation technology. He is an employee, shareholder, and fiduciary officer of Metta Medical dba LEVEL.
Why Sleep Is Active Biology, Not Passive Rest
Before talking about sleep support, supplements, or cannabinoids, it helps to understand what sleep actually is. Most people think of sleep as downtime, a shutdown, or something the brain does when it is done working. Biologically, that framing is backwards.
Sleep is one of the most active and highly organized states the human body enters. While conscious awareness fades, internal systems ramp up. The brain shifts from interacting with the outside world to performing essential maintenance work that cannot happen while awake. When sleep works, it is not because the brain turns off. It is because it switches modes.
What Does the Brain Do During Sleep?
During healthy sleep, the brain and body are performing critical biological functions: consolidating memory and learning 1, 2, regulating emotional tone, recalibrating stress and hormonal signaling, repairing tissue and restoring metabolic balance, and clearing accumulated metabolic waste from the brain 3. That last function deserves specific attention. A landmark 2013 study published in Science demonstrated that the brain’s glymphatic waste clearance system operates primarily during sleep and is dramatically reduced during wakefulness 3. Sleep is not where the brain rests. It is, in part, where the brain cleans itself.
Many of these processes are time-locked to sleep. They do not simply resume later if sleep is missed or fragmented 1. This helps explain a common experience: sleeping for enough hours yet waking unrefreshed. In those cases, duration was present, but proper structure was not.
How Does Sleep Architecture Work?
Sleep is not a single uniform state. It unfolds in repeating cycles, each lasting roughly 90 minutes, with most people experiencing four to six cycles per night 4. Each cycle comprises distinct stages broadly grouped into non-REM and REM sleep. These stages serve different biological purposes, and healthy sleep depends on the brain’s ability to move smoothly through them, repeatedly, across the night 4. This is why being unconscious is not the same as sleeping well.
What Happens During Non-REM Sleep?
Non-REM sleep dominates the first half of the night, especially when sleep pressure is high 4. During deeper non-REM stages, heart rate and blood pressure drop, muscle tone decreases, growth hormone release increases, and immune and inflammatory signaling shift toward tissue repair and restoration 4. These processes tie non-REM sleep closely to physical recovery, metabolic regulation, and stabilization of neural circuits 1. When non-REM sleep is disrupted, people often feel physically depleted, sore, or run down, even if they spent adequate time in bed.
What Happens During REM Sleep?
REM sleep becomes more prevalent in the second half of the night 4. Brain activity increases substantially, daily emotional experiences are processed and contextualized, memories are integrated rather than simply stored 2, and dreaming tends to be most vivid. REM sleep is critical for emotional regulation, stress adaptation, learning, and pattern recognition across recently acquired information 1, 2.
REM is especially sensitive to disruption. Stress, alcohol, late-night light exposure, and irregular sleep timing all preferentially suppress or fragment REM 4. When REM is chronically reduced, the consequences are disproportionately emotional and cognitive: increased reactivity, anxiety, irritability, and impaired judgment are among the most consistently documented effects 5.
What Is the Difference Between Sleep and Sedation?
Because sleep is staged and cyclical, forcing unconsciousness is not the same as supporting sleep. Many substances can shorten the time to unconsciousness while simultaneously altering sleep stage distribution, suppressing REM, and fragmenting the architecture that makes sleep restorative 6. This is why some sleep aids reduce sleep onset time while leaving people groggy, emotionally flat, or cognitively impaired the next day.
Healthy sleep is not defined by how fast you fall asleep. It is defined by whether the brain can cycle naturally and continuously through its stages. The goal of any sleep-supportive strategy is not to override architecture but to allow biological sleep processes to unfold with minimal friction. This distinction is central to understanding how cannabinoids affect sleep.
What Does This Mean for Sleep Support?
Understanding sleep as an active, structured, and time-sensitive biological process reframes what sleep support can reasonably accomplish. The goal is not to override the system. It is to reduce unnecessary arousal, support natural transitions into and within sleep, and improve overall continuity across the night.
Sleep disruption is rarely caused by a single factor, and interventions that address only one variable at a time reflect that same limitation. Arousal, circadian misalignment, stress load, pain, and environmental interference frequently operate simultaneously, and a support strategy that resolves only one of them will encounter a ceiling defined by the others that remain.
This framing is directly relevant to cannabinoids. Cannabinoids interact with regulatory systems that affect stress, pain, arousal, and autonomic tone. They do not replace sleep biology. Their role, when used thoughtfully and consistently, is to modulate the intensity of signals that may be interfering with sleep, not to force sleep itself. How consistently they are used matters more than how much is taken on any given night. The real-world evidence reviewed later in this guide confirms this directly and with specific numbers.
Sleep and Behavior: Why You Are Not Sleeping Well, and Why Supplements Alone Aren’t Enough
For most people, sleep problems are not caused by a broken brain or a missing supplement. They are caused by behavioral friction.
Sleep is a biological process, but it is shaped by how the day unfolds. The brain does not move from wakefulness to sleep on command. It transitions gradually, guided by cues about timing, safety, predictability, and internal balance. When those cues conflict, sleep becomes fragile. This is why two people can use the same sleep product and have very different outcomes.
Why Does Feeling Exhausted Not Guarantee Sleep?
One of the most common misconceptions about sleep is that fatigue alone should guarantee rest. In reality, two forces must align for sleep to occur: sleep pressure, the biological drive that accumulates the longer you stay awake 7; and low arousal, the state in which the nervous system can disengage from vigilance. Arousal, in sleep science, refers to the brain and nervous system being in an activated, alert state, whether mentally, emotionally, or physiologically. It is the system that keeps you online when conditions seem to require it.
Many modern sleep problems occur when sleep pressure is high but arousal remains elevated 5]. This is the familiar experience of feeling exhausted yet wired. In that state, lying in bed longer often makes things worse: effort increases self-monitoring, self-monitoring increases arousal, and arousal further delays sleep. Sleep does not begin when the lights go out. It begins when the brain interprets conditions as safe enough to disengage.
How Does Unresolved Stress Disrupt Sleep?
Stress itself is not inherently harmful to sleep. Acute stress followed by resolution is a normal part of human biology. The problem in modern life is unresolved stress. To the brain, persistent unresolved stress is a continuous instruction to stay alert5. Late-night work, rumination, emotional processing, and anticipatory anxiety all keep arousal systems active well into the night. Even when the body is physically still, the brain may still be running simulations, modeling outcomes, and rehearsing responses. No supplement can reliably override this signal. At best, it can soften it. Durable improvement requires changing the conditions that keep the signal active.
Why Does Light Exposure Affect Sleep Timing?
Light is the strongest external signal shaping sleep timing8. The brain uses light exposure to answer a fundamental biological question: is it day or night? Artificial light in the evening, particularly from screens, delays melatonin onset and shifts sleep timing later even when subjective sleepiness is already present
[8]. Screens compound this by combining bright light with cognitive and emotional arousal, which the brain interprets as daytime input rather than a transition toward rest.
What Do Alcohol and Caffeine Actually Do to Sleep?
Alcohol often shortens sleep onset but fragments sleep across the second half of the night, suppresses REM, and increases awakenings 6. It sedates. It does not restore. The distinction between sedation and restorative sleep described in the previous section applies directly here.
Caffeine blocks adenosine, the molecular signal that accumulates during wakefulness to build sleep pressure 7. Because caffeine’s half-life is typically five to seven hours, afternoon use frequently reduces effective sleep pressure into the night, producing lighter and more fragmented sleep even when subjective fatigue is high 7. For many people, improving sleep does not require eliminating alcohol or caffeine entirely. Rather, it requires making their timing more deliberate and predictable.
Why Does Consistency Matter More Than Optimization?
The brain values predictability more than perfection. Consistent sleep timing, wake timing, meal patterns, and wind-down routines do more for sleep quality than optimal conditions applied inconsistently 8. Erratic schedules force the brain to recalibrate when sleep is supposed to occur, increasing both sleep onset latency and nighttime fragmentation. Most chronic sleep disruption stems from inconsistent behavioral signaling, not insufficient effort or the wrong supplement.
Sleep disruption typically involves elevated arousal, poor circadian alignment, stress load, and environmental interference simultaneously. Approaches that target only one of these variables carry a predictable ceiling. This is why behavioral consistency is not merely a supplementary recommendation alongside cannabinoid use. It is the foundation that determines whether cannabinoid use produces consistent benefit at all.
This is not a theoretical claim. In LEVEL’s real-world observational study of the Sleep Protab, use consistency, defined as the frequency of nights the product was used per week, was the only statistically significant moderator of both validated sleep outcomes 9. Dose amount per night did not predict better outcomes. Consistency did. This finding, drawn from 157 participants over 29 days using validated instruments, is a direct empirical parallel to the behavioral argument this section makes: cannabinoids work best when integrated into consistent routines, not deployed reactively in response to a bad night.
What Actually Sets the Conditions for Sleep to Work?
Most people do not experience the same sleep pattern every night. Sleep changes with stress, travel, light exposure, alcohol use, and schedule consistency. What remains constant is behavior. Behavior sets the baseline conditions from which sleep either succeeds or fails.
If sleep timing is regularly misaligned with the internal clock, even well-matched sleep support will have limited impact 8. If arousal remains elevated from unresolved stress or late-night stimulation, the system has no clear signal that sleep is permitted. Consistent sleep and wake times remain the foundation that makes any support strategy, including cannabinoid use, work better.
What Role Do Cannabinoids Play in This Picture?
This section is not meant to discourage the use of sleep aids or cannabinoids. It is meant to place them in an accurate context.
Most sleep problems are not binary failures. They are the accumulated result of elevated arousal, poor timing, unresolved stress, and inconsistent routines. Understanding this reframes what sleep support can reasonably accomplish. The goal is not to override the brain. It is to reduce friction within a system that is already capable of sleeping well when behavioral conditions allow it.
That is the context in which cannabinoids are most relevant. They interact with regulatory systems that govern stress response, autonomic tone, pain signaling, and arousal 10, 11. When the behavioral foundation is present, those interactions may meaningfully reduce remaining friction. When it is not, cannabinoids are being asked to compensate for misalignment they are not designed to correct. The next section explains the biology of how that interaction works.
The Endocannabinoid System: Sleep Regulation, Not Sedation
If sleep were controlled by a single switch, it would be easy to fix. It is not. Sleep emerges from the coordination of multiple biological systems: stress response, emotional regulation, autonomic balance, pain perception, and circadian timing. When these systems are aligned, sleep unfolds with relative ease. When they are not, sleep becomes fragile. The previous section established that behavior sets the conditions for this alignment. This section explains the biological system through which cannabinoids interact with those conditions.
What Is the Endocannabinoid System?
The endocannabinoid system (ECS) is a distributed regulatory network present throughout the brain and body 10. It includes endogenous cannabinoids produced by the body itself, cannabinoid receptors including CB1 and CB2, and enzymes responsible for synthesizing and degrading signaling molecules. Rather than driving a single physiological function, the ECS modulates signaling intensity across multiple domains simultaneously 10, 11.
This is why the ECS is relevant to sleep. Not because it puts you to sleep but because it participates in regulating the balance across the systems that determine whether sleep can occur and persist.
What Is ECS Tone and Why Does It Matter?
The baseline state of endocannabinoid signaling at any given moment is sometimes referred to as ECS tone10. ECS tone is not a fixed trait and is not directly measurable in routine clinical settings. It reflects the dynamic interplay between stress load, behavioral patterns, sleep history, environmental inputs, and internal physiology. Chronic stress, inconsistent sleep, irregular routines, light exposure, physical activity, and diet all influence endocannabinoid signaling10, 11. This means ECS tone is not something that happens to you. It is something your behavior shapes continuously.
A useful way to understand the ECS is as a biological volume control rather than an on/off switch. It does not initiate sleep or wakefulness directly. Instead, it influences how strongly certain signals are expressed. Stress signaling may be amplified or dampened. Pain perception may be intensified or softened. Emotional reactivity may be heightened or stabilized. The ECS does not determine which signals are present. Rather, it affects their intensity.
How Does the ECS Interact with Sleep Biology?
Endocannabinoid signaling fluctuates throughout the day and interacts with circadian rhythms, stress exposure, physical activity, and sleep deprivation 10. CB1 receptors are densely expressed in brain regions involved in arousal, emotional processing, memory consolidation, and autonomic regulation, all of which play important roles in sleep–wake transitions 11.
Rather than causing sleep, ECS activity appears to influence transitions between states. This includes the transition from wakefulness into sleep and the transition from nighttime awakenings back into sleep 10. These transitions are particularly sensitive to stress load, autonomic activation, and the accumulated signals the nervous system is carrying into the night. Cannabinoids interact with the physiological state they enter. Behavioral context frequently determines whether that interaction produces benefit or instability.
How Do Different Cannabinoids Affect Sleep?
Cannabinoids derived from cannabis interact with the ECS but do so through distinct mechanisms and with distinct pharmacological profiles. Understanding these differences matters because formulation decisions are not interchangeable.
Tetrahydrocannabinol (THC) directly activates CB1 receptors and produces noticeable changes in perception, mood, and sedation 12. At certain doses, THC has been shown to shorten sleep onset and increase slow-wave sleep while suppressing REM sleep, an effect that is well documented and dose dependent 12. At higher doses or with chronic use, THC can disrupt sleep architecture, impair next-day cognition, and produce tolerance that over time, blunts its sleep-supporting effects over time.
CBD exerts modulatory effects through mechanisms that do not involve direct CB1 agonism. Its influence on sleep appears to be primarily indirect, operating through anxiety reduction, autonomic stabilization, and pain modulation rather than sedation 11. Evidence for CBD as a direct sleep agent is mixed, but evidence for its role in reducing the friction that prevents sleep, particularly anxiety and hyperarousal, is more consistent.
CBG has demonstrated binding affinity as an alpha-2 adrenoceptor agonist 14, a mechanism shared with established sleep-relevant compounds such as clonidine 15. This pharmacological profile provides a plausible pathway for CBG’s reported effects on arousal reduction and sleep transitions that is distinct from CB1-mediated sedation.
CBN is widely marketed as the sleep cannabinoid. The evidence for this claim is limited. Most CBN sedation reports derive from older preparations containing residual THC rather than isolated CBN, and controlled studies specifically isolating CBN’s sleep effects are sparse 12, 13. CBN’s sleep-relevant mechanisms, if present, likely operate through pathways other than direct sedation.
THCa is the non-psychoactive acidic precursor to THC and does not directly activate CB1 receptors at typical doses.
It is worth noting that while cannabinoids may interact synergistically in multi-compound formulations, this is distinct from the claim that any combination of cannabinoids will produce additive or amplified effects. Formulation decisions require specificity about which compounds are combined, at what ratios, and for what physiological targets.
This is also why single-cannabinoid interventions, however well-matched to an individual’s pharmacology, operate within a ceiling defined by the complexity of the problem they are addressing. Multi-compound formulations designed around specific physiological targets are not a marketing decision. They are a logical response to multi-factorial disruption.
Further Reading:
Ultimate Guide to Cannabinoids
Why More Is Not Necessarily Better
Because the ECS fine-tunes signaling rather than overrides it, cannabinoids often feel less immediately dramatic than traditional hypnotics 6. They may reduce perceived stress or discomfort that interferes with sleep without necessarily inducing unconsciousness. This is a feature, not a limitation, for anyone whose sleep problem is rooted in elevated arousal rather than insufficient sedation.
At higher doses or in sensitive individuals, cannabinoids, particularly THC, can disrupt normal sleep stage distribution, impair next-day cognition, or produce tolerance 12. Excessive modulation can blunt normal sleep-pressure signals, interfere with circadian dynamics, or introduce night-to-night variability. Dose, timing, formulation, and individual sensitivity all determine whether modulation supports or disrupts sleep architecture.
What Does This Mean for Cannabinoid Use in Sleep Support?
Understanding the ECS in this way reframes how cannabinoids fit into sleep support. The goal is not to force sleep or override architecture artificially. It is to reduce the intensity of signals that may be preventing sleep from unfolding naturally in a system that already has the biological capacity to sleep when conditions allow.
Cannabinoids interact with that system. They do not replace it. Whether that interaction produces consistent benefit depends substantially on the behavioral foundation established before the cannabinoid is introduced and on the specificity of the formulation itself. The next section examines what the clinical and real-world evidence shows about specific cannabinoids and specific sleep outcomes.
The Science: What Cannabinoids Can and Cannot Tell Us About Sleep
Why Sleep Research Is Structurally Difficult
Research on cannabinoids and sleep is expanding, but interpreting it requires understanding why rigorous studies frequently produce ambiguous results. Sleep is simultaneously subjective and physiological, exhibits high night-to-night variability within individuals, and is among the human experiences most sensitive to placebo response. These properties do not reflect a failure of scientific method. They reflect the nature of a regulatory outcome in a complex biological system.
Cannabinoids compound this difficulty. Unlike classical hypnotics that target a single dominant pathway to force a measurable physiological endpoint, cannabinoids modulate multiple upstream systems simultaneously. Their effects on sleep are therefore more likely to appear as patterns across time and populations than as dramatic single-night changes in a controlled laboratory setting. Understanding this is essential for interpreting both positive and null findings correctly.
What the Broader Literature Suggests
Across surveys, observational studies, and smaller controlled trials, several consistent signals emerge in the cannabinoid and sleep literature 12, 13. Improvements in sleep continuity are reported more consistently than increases in total sleep time. Next-day perceived restfulness and mood often improve even when objective sleep duration does not change. Individual responses vary substantially, and placebo responses in sleep studies evaluating cannabinoids are consistently large, a pattern documented across the published literature on cannabis-based therapies for pain and sleep.
These findings do not suggest cannabinoids fix sleep. They suggest cannabinoids can reduce specific forms of friction that interfere with sleep processes and that this reduction is context-dependent, timing-sensitive, and formulation-specific. That distinction is the thesis of this guide.
LEVEL’s Clinical Trial: The First Randomized Placebo-Controlled Study of CBG in Humans
To our knowledge, the study described below is the first randomized, placebo-controlled trial formally evaluating the efficacy and safety of cannabigerol (CBG) in humans16. It was designed not only to generate preliminary efficacy data but to demonstrate that rigorous, IRB-approved, decentralized cannabinoid research in complex underserved populations is feasible.
Study Design
This was a decentralized, triple-blind, randomized, placebo-controlled trial conducted between October 2021 and May 2022 across California (ClinicalTrials.gov NCT05088018; IRB: Advarra Pro00056526)16. Following a two-week run-in phase, participants received LEVEL’s CBG Protab, a highly enriched oral cannabigerol formulation using LEVEL’s activated cannabinoid controlled-release tablet technology, at 25mg daily for two weeks, escalating to 50mg daily for a further two weeks, or matched placebo. Reporting follows CONSORT guidelines.
Population
407 individuals were assessed for eligibility. 63 were randomized (CBG n=33, placebo n=30)[16]. This was a high-complexity population by design: mean age 44.0 years, 77.7% male, with 70% reporting sleep problems persisting for more than five years. Average nightly sleep at baseline was 5.3 hours. Mean baseline MOS-SS SPI-II score was 61.4 out of 100. Over 40% of participants in both groups had PCL-5 scores at or above 33, the validated threshold indicative of probable PTSD. 85.7% of participants reported regular cannabis product use, with 75% reporting daily use.
Completion and Retention
35 participants completed without major protocol deviations (CBG n=18, placebo n=17). Overall study attrition was 12.7%[16]. A cross-study evaluation of 100,000 participants across eight remote digital health studies found median participant retention of only 5.5 days. This fully decentralized trial retained over 87% of participants across six weeks, affirming the feasibility of this trial design in underrepresented populations.
Primary Outcome
The primary endpoint was change in sleep quality measured by the MOS-SS SPI-II questionnaire. MOS-SS SPI-II scores declined numerically in both groups across the treatment period, indicating improved sleep[16]. In the intention-to-treat population, the mean between-group difference in change score from day 14 to day 42 was 4.4 points (95% CI: -4.1 to 13.0) in favor of placebo (p=0.3). In the per-protocol population, the mean between-group difference was 3.8 points (95% CI: -4.8 to 12.0) in favor of placebo (p=0.4). Neither result was statistically significant. These results are reported here without revision.
What the Null Result Actually Means
Both groups improved. The CBG group MOS-SS SPI-II score declined from a mean of 61.2 at baseline to 42.4 at day 42 in the intention-to-treat population, a clinically meaningful absolute reduction. The absence of statistical separation from placebo reflects the magnitude of placebo response in this study, consistent with what the published cannabinoid RCT literature documents consistently12, 13. A null result in this context does not mean CBG had no effect. It means the effect could not be distinguished from expectation in this sample size and population.
The Finding That Directly Supports the Systems-Based Thesis
Post hoc analysis identified a statistically significant responder pattern within the CBG arm16. Participants defined as responders, those showing at least a 10-point improvement in MOS-SS SPI-II during active treatment, were significantly younger (mean age 35.2 years, SD 11.8) than non-responders (mean age 50.8 years, SD 16.2), p=0.011. This finding is directly consistent with a context-dependent, population-specific model of cannabinoid efficacy. CBG did not produce uniform effects. It produced effects that clustered in a specific subpopulation, which is precisely what a systems-based modulation model predicts.
The Autonomic Signal
In participants reporting afternoon dosing, the CBG group demonstrated a statistically significant lower resting heart rate two hours post-dosing compared to placebo (p=0.017)[16]. This is mechanistically relevant. Autonomic tone is one of the upstream regulatory systems that determines whether sleep can occur and persist. The fact that a physiological signal appeared in heart rate but not in self-reported sleep outcomes suggests CBG produced measurable biological modulation that the primary endpoint instrument was not sensitive enough to capture.
Safety and Tolerability
No serious adverse events considered related to study medication were reported
[16]. Five of 33 CBG participants (15.2%) each experienced one non-serious mild adverse event: headache, lethargy, gastric upset, nausea, or hypersomnia. Two participants withdrew. This tolerability profile compares favorably to published survey data reporting adverse events in more than 50% of regular CBG product users in naturalistic settings.
Real-World Data: A Necessary Complement to Controlled Research
Randomized controlled trials answer one question with precision: does this intervention outperform placebo under controlled conditions in a defined population? Real-world observational data answers a different and equally necessary question: how do people actually experience this in daily life, across diverse populations, with flexible use patterns, over meaningful time horizons?
These are not competing evidence types. They are complementary lenses. The absence of a placebo arm means real-world effect sizes include expectancy contributions that cannot be partitioned. That limitation is real and should be acknowledged. It does not make the findings uninformative. It makes them differently informative.
LEVEL conducted a real-world observational study of its multi-cannabinoid Sleep Protab formulation using the MoreBetter ecological momentary assessment platform 9. The study enrolled 206 participants, with an analytic sample of N=157 for longitudinal outcomes and N=112 for final survey items. The design was a 29-day within-participant structure: a 7-day no-product baseline phase followed by 21 days of product use, with daily and weekly assessments throughout. No randomization, no blinding, and no placebo control were employed. These limitations are stated explicitly because accurate interpretation of the findings depends on them.
The population was predominantly female (63.7%), modal age 41 to 50, and largely cannabinoid-naive: 75% had never used a CBN product, 83.93% had never used CBG for sleep, and 57.14% had never used THC for sleep.
Primary outcomes were assessed using two validated instruments. The PROMIS Sleep Disturbance Short Form 8b declined from a pre-product mean of 59.18 to a product-use mean of 53.58, a reduction of 5.59 points that met the published minimally important difference threshold (p<0.05, N=157) [9]. The WHO-5 Well-Being Index rose from a pre-product mean of 42.48 to 54.22, crossing the validated clinical threshold from Poor to Good Well-Being, a 27.63% improvement (p<0.05, N=157) 9.
Sleep quality improved 21.23% on a nightly 0–10 rating scale. Nightly sleep duration increased by approximately 27 minutes during the product-use phase, with the Day 0 to Day 29 endpoint comparison showing a 41-minute gain from 5 hours 25 minutes to 6 hours 7 minutes [9]. The probability of anxiety impacting falling asleep dropped from 81.78% at Day 0 to 23.56% at Day 29, a 58.22 percentage point reduction. The probability of pain impacting sleep declined 38.68% in relative terms.
Nighttime awakening frequency declined from a mean of 2.84 events per night during baseline to 2.14 during product use, a reduction of 0.70 events per night (24.66%, p<0.05) 9. Ability to fall back asleep after awakening improved 20.58%. The Day 0 to Day 29 endpoint comparison for nighttime waking frequency did not reach statistical significance (p>0.05), a discrepancy with the longitudinal model result that is reported here transparently.
The single most dramatic finding in the dataset was next-morning refreshment. The probability of feeling refreshed upon waking rose from 19.39% during baseline to 63.44% during product use, a 44.04 percentage point absolute increase representing a 227% relative change (p<0.05) 9. Morning mood improved 10.63%. Daytime productivity probability increased from 70.64% to 80.03%.
The moderator analysis produced the finding most directly relevant to the thesis of this guide. Dose amount per night did not significantly moderate either validated outcome. Use Consistency, defined as frequency of nights the product was used per week, was the only statistically significant moderator of both WHO-5 and PROMIS outcomes 9. The High Use Consistency subgroup (mean 5.4 nights per week, N=25) showed the largest absolute gains and began with the highest baseline sleep disturbance, finishing with the lowest. Taking more tablets on a given night did not drive better validated outcomes. Using the product consistently across nights did.
Adverse events were generally mild and infrequent. 7.6% of product-use day responses endorsed a hangover effect. Across the 21-day observation period, 21% of participants reported one or more negative effects, with a mean severity of 3.88 out of 10 among those affected 9. The most commonly reported effects were dry mouth, fatigue, sedation, headache, and dry eyes. No serious adverse events were reported.
Reconciling Controlled Trials and Real-World Evidence
Taken together, LEVEL’s clinical and real-world evidence spans two distinct formulations and two distinct study designs9, 16. The single-compound CBG Protab trial established tolerability, demonstrated a context-dependent responder pattern, and produced a statistically significant autonomic signal consistent with ECS modulation of sympathetic tone. The multi-cannabinoid Sleep Protab observational study demonstrated that broader formulation coverage, applied consistently over time, produced validated improvements in sleep disturbance, well-being, sleep continuity, and next-morning restfulness across a general population. The progression from single-compound to multi-compound evidence is not incidental. It reflects a deliberate research strategy built on the premise that sleep disruption is multi-factorial and that formulation coverage, not dose escalation, is the appropriate response to that complexity.
What the Science Does Not Support
Current evidence does not support claims that cannabinoids cure insomnia, replace sleep medications universally, eliminate the need for behavioral change, work equally well for everyone, or show linear dose-response benefits for sleep outcomes. Any narrative suggesting otherwise misrepresents both the biology of sleep and the pharmacology of cannabinoids. That includes narratives produced by this industry with regularity.
Cannabinoids and Sleep: Why No Single Compound Owns the Outcome
When people ask which cannabinoid is best for sleep, they are usually asking the wrong question.
Sleep is not a single biological event. It is an outcome shaped by mental state, emotional tone, autonomic balance, physical comfort, circadian timing, and sleep continuity across the night. Different cannabinoids influence different parts of this landscape through distinct mechanisms. None of them controls it independently. This is why sleep outcomes with cannabinoids vary so widely between individuals, and why single-compound sleep products so consistently disappoint.
Do Cannabinoids Target Sleep Directly?
Cannabinoids do not bind to a sleep receptor, and they do not initiate sleep the way sedatives do. Instead, they influence upstream regulatory systems that determine whether sleep can occur and whether it can persist, precisely the systems described in the previous section on the endocannabinoid system.
In sleep contexts, cannabinoids most commonly affect stress and emotional arousal, autonomic nervous system tone, physical discomfort, sleep continuity and return-to-sleep, and next-morning state. Understanding cannabinoids through these functional dimensions is more useful than assigning them to sleep stages or marketing labels. The relevant question is not which cannabinoid puts you to sleep. It is which cannabinoid addresses the specific signal that is preventing your system from transitioning into or maintaining sleep.
What Does CBD Do for Sleep?
CBD is often described as relaxing, but its effects are better understood as anxiolytic (anxiety-reducing) and regulatory rather than sedating 11, 12. In sleep contexts, CBD tends to be most relevant when sleep is disrupted by racing thoughts, stress-related arousal, anticipatory anxiety, or difficulty disengaging mentally from the day. Its influence on sleep appears to operate primarily through anxiety reduction, autonomic stabilization, and modulation of hyperarousal rather than through direct sleep induction 11.
CBD does not reliably initiate sleep on its own, and higher doses are not consistently better. In some individuals, high-dose CBD can feel neutral or mildly activating. Its value is in reducing the cognitive and emotional friction that prevents the nervous system from interpreting conditions as safe enough to disengage.
What Does CBG Do for Sleep?
CBG does not map cleanly onto arousal or sedation. Its pharmacological profile is distinct from other cannabinoids and provides a specific mechanistic rationale for its role in sleep contexts. CBG has demonstrated nanomolar to sub-nanomolar affinity as an alpha-2 adrenoceptor agonist 14, a mechanism shared with clonidine, an established compound with documented effects on sleep in PTSD populations 15. This adrenergic pathway is separate from CB1-mediated sedation and suggests CBG’s primary relevance is in autonomic regulation and arousal modulation rather than sleep induction.
LEVEL’s IRB-approved randomized controlled trial of oral CBG in US military veterans, the first placebo-controlled study of CBG in humans, found that post hoc analysis identified a statistically significant responder subgroup among younger participants (mean age 35.2 years versus 50.8 years in non-responders, p=0.011) [16]. A statistically significant reduction in resting heart rate was also observed in afternoon-dosing participants (p=0.017), consistent with the alpha-2 adrenergic mechanism 16. These findings support a context-dependent model of CBG efficacy that aligns with the systems-level thesis of this guide.
What Does CBN Do for Sleep?
CBN is frequently marketed as the sleep cannabinoid, but that framing overstates the current evidence. CBN does not reliably help people fall asleep faster, and the sedation commonly attributed to CBN in older reports is now understood to have derived largely from residual THC in preparations that were not isolating CBN specifically 12, 13. Controlled studies evaluating isolated CBN’s sleep effects are sparse, and the mechanistic basis for CBN-specific sedation has not been clearly established.
What the available evidence does suggest is that CBN may be more relevant to sleep continuity and return to sleep than to sleep onset 12, 13. CBN may be most useful for individuals who fall asleep without difficulty but experience fragmented sleep across the night. Timing sensitivity applies here: taken too early or at inappropriate intervals, CBN can sometimes disrupt later sleep architecture rather than support it.
What Does THCa Do for Sleep?
THCa is the non-psychoactive acidic precursor to THC. It does not directly activate CB1 receptors at typical oral doses and does not produce intoxication. The mechanistic basis for this distinction is structural: acidic cannabinoids display increased polarity relative to their neutral counterparts, which is consistent with lower blood–brain barrier penetration and relatively greater peripheral engagement 19. This means THCa’s pharmacological activity is weighted toward peripheral tissues rather than central psychoactive pathways.
THCa has demonstrated inhibition of COX-1 and COX-2 enzymes in preclinical work 18, the same enzymatic pathway targeted by nonsteroidal anti-inflammatory drugs. This establishes mechanistic plausibility for anti-inflammatory and analgesic activity through a pathway independent of CB1 receptor engagement. The standard qualification applies: in vitro enzyme inhibition does not automatically confirm clinical efficacy, and whether oral dosing produces plasma concentrations sufficient for meaningful COX inhibition in humans has not been confirmed in published pharmacokinetic trials.
It is also worth noting that acidic cannabinoids, including THCa, have been detected systemically following oral ingestion, and no rapid human decarboxylase has been identified that would guarantee immediate conversion to THC upon ingestion 20. This supports the position that THCa in a stable oral formulation may exert its own pharmacological activity rather than functioning solely as a THC precursor.
THCa was a core component of LEVEL’s founding cannabinoid formulation thesis, which identified acidic cannabinoids as a pharmacologically distinct category with effects not accessible from neutral cannabinoid preparations alone. The full physiological case for acidic cannabinoids, including their peripheral distribution profile, COX enzyme interactions, 5-HT1A receptor activity, and in vivo stability evidence, is examined in depth in LEVEL’s canonical guide to acidic cannabinoids [link to be inserted at publication].
THCa’s contribution to sleep is indirect and peripheral: by addressing physical discomfort that would otherwise sustain arousal, it supports the conditions under which the nervous system can transition toward sleep. It does not address cognitive or emotional arousal and is not a standalone sleep intervention.
Why Do Single-Compound Approaches Typically Fall Short?
Each cannabinoid influences a different dimension of the sleep problem. Most sleep problems are multi-dimensional. Calming cognitive arousal without addressing physical discomfort may still produce awakenings. Improving comfort without lowering stress may delay sleep onset. Supporting continuity without stabilizing baseline autonomic tone may help on some nights and fail on others. Escalating the dose of a single compound does not resolve these gaps. It amplifies one signal while leaving the others unaddressed.
This is the ceiling that single-variable interventions encounter. It is not a failure of the specific compound. It is a structural consequence of addressing a multi-factorial problem with a single tool. Formulation coverage that matches the distributed nature of the problem is a logical response to that complexity, not a marketing position.
Why Do Multi-Compound Formulations Work Better?
Well-designed cannabinoid combinations allow for broader coverage of sleep-relevant friction points, lower effective doses of each individual compound, and fewer tradeoffs than high-dose single-compound use. In LEVEL’s real-world observational study of the Sleep Protab, a multi-cannabinoid formulation, participants showed improvements across every primary sleep metric measured using validated instruments over 29 days9. Critically, the only statistically significant moderator of outcomes was use consistency, not dose amount. The benefits that emerged from a multi-compound formulation were realized through consistent application within a behavioral routine, not through dose escalation.
Does Context Still Determine the Outcome?
Even well-designed multi-compound formulations cannot compensate for severe circadian misalignment, chronic sleep deprivation, or persistent behavioral disruption. Cannabinoids work best when they enter a system that behavior has already oriented toward sleep. They refine conditions. They do not create them. The formulation addresses the what. Behavior and timing address the when and the whether. All three are required for consistent outcomes.
How to Use Cannabinoids for Sleep: Timing and Context Matter More Than Dose
Most frustration with sleep-focused cannabinoids does not come from weak products. It comes from misalignment between a person’s sleep pattern, when cannabinoids are used, and what they are expected to do.
Cannabinoids are not replacements for sleep. They are supports for sleep-relevant transitions. They work best when they reduce specific friction points that interfere with sleep biology. They work poorly when asked to override it. Before thinking about dose or formulation, the most important question is: where does your sleep break down?
What Is Your Dominant Sleep Pattern?
Sleep problems are often described in terms of hours slept, but that metric is frequently misleading. What matters more is when sleep fails. Most people experience one of three primary patterns more consistently than the others, and identifying the dominant pattern is the prerequisite for any useful timing or formulation decision.
The first pattern is difficulty falling asleep. The body feels tired but the mind remains active. Stress, anticipation, or rumination delays the transition into sleep. This is primarily a sleep-onset problem, driven by a nervous system that has not fully downshifted or disengaged from the demands of the day.
The second pattern is falling asleep easily but waking after a few hours. Sleep begins without difficulty, but an awakening occurs after roughly three to five hours, and returning to sleep feels effortful despite continued fatigue. This is a return-to-sleep problem, not a sleep-drive problem.
The third pattern is fragmented or light sleep. Awakenings are frequent, continuity is poor, and sleep feels shallow or easily disrupted throughout the night. This is a sleep-maintenance problem rather than an initiation issue and typically reflects persistent low-level arousal across the entire sleep period.
Most people do not fit perfectly into one pattern every night. These categories describe where sleep breaks down most often, not a fixed identity. If sleep timing is consistently misaligned with your internal clock, even well-matched support will have limited impact regardless of formulation.
How Should Timing Match the Pattern?
Once the dominant pattern is clear, timing becomes the most consequential variable in cannabinoid use for sleep. In LEVEL’s real-world observational study, use consistency was the only statistically significant moderator of validated sleep outcomes [9]. Dose amount per night did not predict better results. This finding applies directly to timing: consistent use within a predictable nightly routine outperforms reactive use at escalating doses.
When falling asleep is the problem, cannabinoids are typically most effective when taken shortly before bedtime as part of a consistent wind-down routine. In this context, cannabinoids may reduce cognitive noise, soften stress-related nervous system arousal, and support the transition from vigilance to rest. The cannabinoid does not create the transition. It reduces friction within a transition the behavior has already begun. When staying asleep or returning to sleep is the problem, taking cannabinoids at bedtime is frequently counterproductive. In many cases, cannabinoids are more effective when taken after waking during the night, at the moment sleep is attempting to resume. Increasing the bedtime dose in this pattern often worsens outcomes rather than improving them because the timing is misaligned with where the sleep system is actually failing.
Why Does Dose Escalation Typically Backfire?
A common response when sleep does not improve is to increase dose. This frequently produces the opposite of the intended effect. Because cannabinoids modulate rather than sedate, excessive use can blunt necessary signaling, increase restlessness, disrupt sleep-stage transitions, and introduce inconsistency across nights12. Better results come from adjusting timing, context, and formulation rather than escalation.
How Do Food and Absorption Affect Consistency?
Because cannabinoids are lipophilic, oral absorption is meaningfully influenced by the presence of dietary fat 17. Taking cannabinoids with a small amount of fat-containing food, a spoonful of yogurt, a small portion of cheese, a handful of nuts, or a teaspoon of olive oil, can improve absorption consistency and produce more predictable onset timing than administration on a completely empty stomach. This reduces one source of night-to-night variability that many people attribute incorrectly to the product itself.
Consistency of administration method matters as much as consistency of timing. Taking cannabinoids the same way each night, in the same food context, at thesame time relative to sleep, improves predictability and makes it substantially easier to interpret results accurately.
When Should You Reassess?
Cannabinoid use for sleep should stabilize sleep patterns over time, not introduce variability. Next-day function should improve. Specific signals that indicate reassessment include escalating dose without improvement in outcomes, increased nighttime awakening frequency relative to baseline, next-day grogginess or cognitive impairment, and diminishing effects despite consistent use. These signals almost always indicate a mismatch in timing, formulation, or behavioral context rather than a need for stronger or higher-dose compounds.
What Can and Cannot Cannabinoids Do for Sleep?
Cannabinoids may meaningfully reduce sleep-onset friction, improve sleep continuity, support return-to-sleep after awakenings, and improve next-morning perceived restfulness. These are the outcomes documented across LEVEL’s clinical and real-world research[9, 16]. Cannabinoids will not override chronic sleep deprivation, correct circadian misalignment independently, replace the behavioral changes that address underlying disruption, or work identically across individuals. Consistent timing, light management, stress resolution, and wind-down routines remain the foundation. Cannabinoids reduce friction within that foundation. They do not substitute for it.
Finding the Right Sleep Formula: Coverage Over Intensity, Systems Over Single Compounds
Once sleep patterns and timing are understood, attention often shifts to formulation. A sleep formula is not a solution by itself. It is a refinement tool. Formulation works best when it supports a system already oriented toward sleep through behavior, timing, and circadian alignment. When formulation is asked to compensate for misalignment elsewhere, its effects become limited and inconsistent regardless of how well-designed the product is.
Why Start With Friction Rather Than Ingredients?
A common and understandable mistake is beginning with an ingredient list rather than the underlying problem. The more productive starting point is the same question raised when discussing timing: what form of friction is most consistently interfering with sleep right now?
Across individuals, sleep disruption typically involves one or more overlapping factors: cognitive or emotional activation, autonomic instability, physical discomfort, fragile sleep continuity, and difficulty returning to sleep after awakening. These factors explain why sleep breaks down, not just when it breaks down. Effective formulation targets these friction points rather than sleep stages alone. Sleep pattern tells you when the system is failing. Friction tells you why. Two people with identical sleep maintenance complaints may require meaningfully different formulations depending on whether stress, physical discomfort, or regulatory instability is driving the disruption.
What Is the Difference Between Coverage and Intensity?
One of the most consequential distinctions in cannabinoid formulation is coverage versus intensity, and it is worth defining both precisely.
Intensity increases the strength of a single signal by escalating the dose of one compound. Coverage reduces multiple sources of friction simultaneously using complementary compounds at lower individual doses. These are not equivalent strategies, and they do not produce equivalent outcomes for sleep.
High-dose single-compound approaches increase intensity without expanding coverage. This frequently leads to diminishing returns, paradoxical effects at higher doses, next-day impairment, and inconsistent night-to-night results 12. The ECS is a distributed modulatory system. Concentrating intervention on a single pathway does not compensate for disruption originating in adjacent systems.
Multi-cannabinoid formulations designed around specific friction profiles address more than one sleep-relevant dimension, require less total cannabinoid load per compound, and tend to produce more stable results across nights 9, 16. For sleep, coverage and consistency outperform intensity consistently. In LEVEL’s real-world observational data, use consistency was the only statistically significant moderator of validated outcomes; dose amount per night was not 9.
How Do Friction Profiles Map to Formulation Logic?
The following profiles illustrate formulation reasoning rather than prescriptions. Individual responses vary, and formulation should be adjusted thoughtfully based on observed outcomes rather than escalated aggressively.
When sleep is delayed by racing thoughts, anticipatory anxiety, or stress-related activation, formulations that support emotional regulation and nervous system downshifting tend to outperform sedating approaches. The goal is reducing cognitive and emotional arousal that prevents the nervous system from interpreting conditions as safe enough to disengage.
When sleep feels inconsistent or fragile across nights rather than acutely disrupted on a given night, the issue is often baseline autonomic tone rather than a single identifiable stressor. Formulations that support regulatory stability tend to outperform those designed to force sleep onset.
When pain, musculoskeletal tension, or inflammatory discomfort are present, sleep disruption is frequently secondary to physical arousal the nervous system cannot ignore. Improving physical comfort through peripheral cannabinoid modulation can indirectly support both continuity and depth of sleep.
When sleep begins normally but fails to continue, formulation needs to support smooth re-entry into sleep rather than initiation. This is where the interaction between formulation and timing is most direct.
Why Does Formulation Matter More Later in the Night?
Sleep onset is heavily influenced by behavior and circadian alignment. Later-night sleep depends more on how neurophysiological arousal rebounds after normal awakenings and how readily the system can re-enter sleep. This distinction matters for formulation design because the compounds most relevant to sleep onset are not necessarily the same compounds most relevant to sleep continuity.
Real-world data from LEVEL’s Sleep Protab observational study supports this directly [9]. The most dramatic single finding across 157 participants over 29 days was next-morning refreshment: the probability of feeling refreshed upon waking rose from 19.39% during baseline to 63.44% during product use. Nighttime awakening frequency declined by 24.66%, and ability to return to sleep improved by 20.58%. These continuity and next-morning outcomes exceeded the sleep onset findings in magnitude, consistent with the hypothesis that multi-cannabinoid formulation coverage has its greatest impact on the second half of the night.
How Should Individual Variability Be Interpreted?
No formulation works identically for everyone. Responses vary based on baseline ECS tone, current stress load, accumulated sleep debt, prior cannabinoid experience, and concurrent medications or supplements. This variability is not a product failure, and it is not noise. It is an inherent feature of systems-level modulation in which the same input enters different physiological states and produces state-dependent outputs.
Formulation should be adjusted thoughtfully based on observed pattern, timing, and friction rather than escalated aggressively. When outcomes are inconsistent, the most productive question is whether the formulation is matched to the friction profile and whether the behavioral foundation is in place.
What Is the Role of Formulation Within the Larger System?
Cannabinoid formulations work best when they help lower the barrier to transitions that are already trying to occur, support sleep continuity within a system that behavior has already oriented toward rest, and integrate into consistent routines that the nervous system can learn to anticipate. They work poorly when asked to override chronic sleep deprivation, compensate for erratic schedules, or correct circadian misalignment that behavior has not addressed.
What Three Principles Should Guide Cannabinoid Use for Sleep?
This guide has built toward three conclusions that are now supported by both the biological evidence and the clinical and real-world data reviewed in the Science section.
Sleep disruption is multi-factorial. It involves arousal, circadian misalignment, stress, physical discomfort, and regulatory instability operating simultaneously. Interventions that address only one variable encounter a ceiling defined by the variables they leave unaddressed.
Cannabinoids modulate friction rather than force sleep. They interact with the physiological state they enter. When that state has been shaped by behavior and timing toward sleep, cannabinoid modulation reduces remaining friction. When it has not, cannabinoids are being asked to compensate for misalignment they are not designed to correct.
Effective formulation prioritizes coverage over intensity. Multi-compound formulations designed around specific friction profiles outperform high-dose single-compound approaches because the problem is distributed and the solution needs to match that distribution. These are not principles derived from product marketing. They are conclusions from sleep biology, endocannabinoid system pharmacology, a peer-reviewed randomized controlled trial 16, and a 29-day real-world observational study 9.
Safety, Expectations, and Limitations: Clear Boundaries Preserve Trust and Outcomes
Cannabinoids can be useful tools for sleep. They are not neutral, and they are not universal. When people are disappointed by sleep products, it is rarely because the compounds are unsafe or ineffective. More often, expectations were misaligned with what cannabinoids are biologically capable of doing. This section sets those boundaries explicitly.
Are Cannabinoids Sedatives?
Cannabinoids do not act like traditional sleep medications. They do not reliably force unconsciousness, and they do not override the arousal pathways that may be preventing sleep in a given individual on a given night. They do not produce uniform effects across individuals, and they do not guarantee sleep on demand. This is not a weakness of the compounds. It reflects a modulatory mechanism rather than a sedative one. Cannabinoids influence the regulatory systems that facilitate sleep when conditions are right. They do not replace sleep biology or substitute for the conditions that make sleep possible.
Do Cannabinoids Cause Dependence?
Cannabinoid formulations without delta-9 THC are generally considered non-habit-forming in the pharmacological sense 12. They do not activate reward pathways the way benzodiazepines, Z-drugs, or alcohol do, and they do not produce classical withdrawal syndromes upon discontinuation 6. This is a meaningful safety distinction from most conventional sleep medications.
Psychological reliance can still develop when cannabinoids are used as a substitute for behavioral change rather than as support for it. When sleep routines degrade and cannabinoids are asked to compensate for that degradation, effectiveness declines. Used intentionally within a behavioral foundation, cannabinoids can support sleep consistently. Used reactively as a replacement for that foundation, they lose their value progressively.
What Can Cannabinoids Reasonably Support?
Based on current clinical and real-world evidence, cannabinoids used in appropriate formulations at appropriate timing may meaningfully support reduced cognitive and emotional arousal at sleep onset, improved sleep continuity across the night, easier return to sleep following nighttime awakenings, and improved next-morning perceived restfulness 9, 16.
These effects are context-dependent, timing-sensitive, substantially more subtle than sedative drugs, and cumulative rather than immediate. They reflect modulation of upstream regulatory systems rather than direct induction of sleep. It is worth noting that other non-pharmacological approaches, consistent wind-down routines, breathwork, light management, and stress regulation address some of the same upstream friction points. Cannabinoids are a specific tool with a specific mechanism, and their value is most apparent when behavioral approaches alone have not been sufficient to address the remaining disruption.
What Are Cannabinoids Unlikely to Fix?
Cannabinoids are unlikely to meaningfully improve sleep when the underlying issue is chronic sleep deprivation that requires recovery sleep rather than friction reduction, severe circadian misalignment that behavior has not addressed, untreated sleep disorders such as obstructive sleep apnea where the physiological disruption is mechanical rather than regulatory, persistent environmental disruption that continues to activate arousal systems, heavy or regular nighttime alcohol use that suppresses REM and fragments sleep architecture, or highly irregular sleep–wake schedules that prevent the circadian system from establishing predictable timing8, 12. In these conditions, cannabinoids may temporarily blunt perceived symptoms without resolving the underlying cause. This is not a failure of cannabinoids. It is a defined boundary of what modulatory intervention can accomplish.
When Should Cannabinoid Use Be Reassessed?
Cannabinoid use for sleep should stabilize sleep patterns over time, not introduce variability. Next-day function should improve. If continued use feels increasingly forceful rather than supportive, or if next-day function is declining, reassessment is warranted.
Specific signals that indicate reassessment include escalating dose without improvement in outcomes, increased nighttime awakening frequency relative to baseline, next-day grogginess or cognitive impairment, and diminishing effects despite consistent use. These signals almost always indicate a mismatch in timing, formulation, or behavioral context rather than a need for stronger compounds 12. Treating them as a dosing problem typically makes them worse.
What Are the Safety Considerations?
Cannabinoids are generally well tolerated across the published clinical and real-world literature 9, 16. In LEVEL’s CBG Protab randomized controlled trial, only 15.2% of participants reported a single mild adverse event over six weeks, with no serious adverse events attributed to the study product 16. In the Sleep Protab real-world study, 7.6% of product-use days were associated with a hangover effect, with negative effects rated at a mean severity of 3.88 out of 10 among the minority who experienced them 9.
Anyone using prescription medications that affect sleep, mood, or cognition should consult their physician before introducing a cannabinoid regimen, as interactions with sedative–hypnotics, anxiolytics, and certain antidepressants are possible 12. Starting conservatively, remaining consistent, and observing patterns over time produces more useful information than pursuing immediate and dramatic effect.
How Do Expectations Shape Outcomes?
Expectations are among the most consequential variables in sleep support and among the least discussed. When cannabinoid formulations are framed accurately, as tools that reduce friction within a system already capable of sleeping well, as complements to behavioral foundations rather than replacements for them, and as modulators that work best with consistency rather than escalation, they tend to perform well relative to that framing.
When they are framed as solutions to exhaustion, replacements for sleep hygiene, or agents capable of overriding biology, they tend to disappoint, not because the compounds have changed but because the conditions being asked of them are outside what modulation can deliver.
Sleep is not a performance to optimize or a problem to conquer. It is a biological process the body already knows how to do. The goal of sleep support is to reduce the friction that prevents that process from unfolding, not to force an outcome the system is not yet positioned to sustain.
What Does This Guide Conclude?
Across this guide, a consistent and evidence-supported picture has emerged.
Sleep is an active, structured biological process shaped by behavior and circadian alignment. The conditions behavior creates determine whether sleep can occur and persist regardless of what support tools are introduced.
The endocannabinoid system regulates signaling balance across the systems that govern sleep, stress, autonomic tone, pain, and emotional regulation. Cannabinoids interact with that regulatory system. They do not replace it or override it.
Sleep disruption is multi-factorial. Single-variable interventions, whether behavioral or pharmacological, encounter a ceiling defined by the variables they leave unaddressed. Multi-compound formulations designed around specific friction profiles are a logical response to that complexity, not a marketing position.
Timing and consistency matter more than dose. The only statistically significant moderator of validated sleep outcomes in LEVEL’s 29-day real-world study was use consistency, not dose amount 9. This finding is a direct empirical expression of the thesis this guide has argued throughout.
When cannabinoids are used with accurate understanding of what they can and cannot do, within a behavioral foundation that has already oriented the system toward sleep, in formulations matched to the specific friction pattern present, and with consistency rather than escalation, they can meaningfully contribute to better sleep over time 9, 16. Not perfect sleep. Not sleep on demand. More consistent, more continuous, more restorative sleep that compounds across nights rather than delivering a single dramatic effect.
That is what the evidence supports. That is what this guide has argued. And that is the standard against which cannabinoid sleep products should be evaluated.
References
1. Diekelmann S, Born J. The memory function of sleep. Nature Reviews Neuroscience. 2010;11(2):114-126. https://doi.org/10.1038/nrn2762
2. Rasch B, Born J. About sleep’s role in memory. Physiological Reviews. 2013;93(2):681-766. https://doi.org/10.1152/physrev.00032.2012
3. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. https://doi.org/10.1126/science.1241224
4. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. 5th ed. Philadelphia: Elsevier Saunders; 2011. p. 16-26.
5. McEwen BS. Sleep deprivation as a neurobiologic and physiologic stressor. Annals of the New York Academy of Sciences. 2006;1056(1):61-71. https://doi.org/10.1196/annals.1352.003
6. Roehrs T, Roth T. Insomnia pharmacotherapy. Sleep Medicine Reviews. 2012;16(2):99-111. https://doi.org/10.1016/j.smrv.2011.03.001
7. Borbely AA. A two process model of sleep regulation. Human Neurobiology. 1982;1(3):195-204. PMID: 7185792
8. Czeisler CA. Stability, precision, and near-24-hour period of the human circadian pacemaker. Recent Progress in Hormone Research. 1999;54:1-43. PMID: 10548871
9. Emerson CR et al. LEVEL Sleep Protab real-world observational study conducted on the MoreBetter platform. 2024. [Internal data on file. Citation format to be updated at publication.]
10. Hillard CJ. Endocannabinoids and the stress response. Neuropharmacology. 2018;124:102-111. https://doi.org/10.1016/j.neuropharm.2017.09.033
11. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease: successes and failures. Trends in Pharmacological Sciences. 2013;34(9):493-505. https://doi.org/10.1016/j.tips.2013.07.002
12. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports. 2017;19(4):23. https://doi.org/10.1007/s11920-017-0775-9
13. Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Medicine Reviews. 2020;53:101339. https://doi.org/10.1016/j.smrv.2020.101339
14. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics. 2021;376(2):204-212. https://doi.org/10.1124/jpet.120.000340
15. Naguy A. Clonidine use in psychiatry: panacea or panache. Pharmacology. 2016;98(1-2):87-92. https://doi.org/10.1159/000446441
16. Emerson CR, Webster CE, Daza EJ, Klamer BG, Tummalacherla M. Effect of cannabigerol on sleep and quality of life in Veterans: a decentralized, randomized, placebo-controlled trial. Medical Cannabis and Cannabinoids. 2026;9:1-14. https://doi.org/10.1159/000549902
17. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology. 2018;9:1365. https://doi.org/10.3389/fphar.2018.01365
18. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biological and Pharmaceutical Bulletin. 2011;34(5):774-778. https://doi.org/10.1248/bpb.34.774
19. [PENDING: Peripheral CB1 distribution and acidic cannabinoid blood-brain barrier penetration reference. To be confirmed from acidic cannabinoids canonical piece.]
20. [PENDING: Acidic cannabinoid systemic detection following oral ingestion reference. To be confirmed from acidic cannabinoids canonical piece.]
